Investigation of individualized treatment for AMD patient with QOL improvement

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462641
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Ophthalmology
• Research Institution: Kyushu University
• Principal Investigator: Oshima Yuji 九州大学, 大学病院, 特別教員 (00536237)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 眼科学 / 分子生物学 / 眼生化学

Outline of Final Research Achievements

Although there was no correlation between visual acuity change after AMD treatment and genetic polymorphism, there was significant correlation between central retinal thickness change and genetic polymorphism. The effect of anti-VEGF therapy for AMD patient may concern to inflammation, because this polymorphism related to inflammation.
The visual acuity and central macular thickness after aflibercept treatment with polypoidal choroidal vasculopathy (PCV)patient, one type of AMD, improved significantly compared to baseline. This result suggested that aflibercept mono therapy is effective for PCV treatment. The score of QOL of AMD patient was significantly improved after anti-VEGF treatment. This results suggested that anti-VEGF therapy for AMD patients are effective morphologically and functionally.

Free Research Field

医歯薬学